How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/type-2-diabetes-mellitus-treatment-adjunct.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Type 2 Diabetes Mellitus Treatment Adjunct — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Type 2 Diabetes Mellitus Treatment Adjunct (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Type 2 Diabetes Mellitus Treatment Adjunct, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Symlin	PRAMLINTIDE	Astrazeneca Ab		Amylin receptor AMY2, Amylin receptor AMY1, Amylin receptor AMY3	2005-01-01
Byetta	EXENATIDE	AstraZeneca	GLP-1 Receptor Agonist [EPC]	Glucagon-like peptide 1 receptor	2005-01-01
Byetta	Byetta	AstraZeneca	GLP-1 Receptor Agonist [EPC]	Glucagon-like peptide 1 receptor	2005-01-01
Welchol	COLESEVELAM	Cosette	Bile Acid Sequestrant		2000-01-01
Parlodel	BROMOCRIPTINE	Esjay Pharma	Ergot Derivative	D(2) dopamine receptor	1978-01-01
Bydureon	Bydureon	Phoenix VA Health Care System		Glucagon-like peptide 1 receptor, Glucagon-like peptide 1 receptor
Welchol	Welchol	Daiichi Sankyo
Bromocriptin	Bromocriptin	University Hospital, Bonn		5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 2 drugs in Type 2 Diabetes Mellitus Treatment Adjunct
Astrazeneca Ab · 1 drug in Type 2 Diabetes Mellitus Treatment Adjunct
Cosette · 1 drug in Type 2 Diabetes Mellitus Treatment Adjunct
Daiichi Sankyo · 1 drug in Type 2 Diabetes Mellitus Treatment Adjunct
Esjay Pharma · 1 drug in Type 2 Diabetes Mellitus Treatment Adjunct
Phoenix VA Health Care System · 1 drug in Type 2 Diabetes Mellitus Treatment Adjunct
University Hospital, Bonn · 1 drug in Type 2 Diabetes Mellitus Treatment Adjunct

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Type 2 Diabetes Mellitus Treatment Adjunct:

Cite this brief

Drug Landscape (2026). Type 2 Diabetes Mellitus Treatment Adjunct — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/type-2-diabetes-mellitus-treatment-adjunct. Accessed 2026-06-10.

Type 2 Diabetes Mellitus Treatment Adjunct full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing